MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.250
+0.010 (0.81%)
At close: Apr 28, 2026, 4:00 PM EDT
1.250
0.00 (0.00%)
Pre-market: Apr 29, 2026, 4:08 AM EDT
Company Description
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer.
Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Vlad Vitoc |
Contact Details
Address: 444 West Lake Street, Suite 1700 Chicago, Illinois 60606 United States | |
| Phone | 312 416 8592 |
| Website | maiabiotech.com |
Stock Details
| Ticker Symbol | MAIA |
| Exchange | NYSEAMERICAN |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vlad Vitoc M.B.A., M.D. | Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors |
| Jeffrey C. Himmelreich M.B.A. | Head of Finance and Principal Financial and Accounting Officer |
| Dr. Sergei M. Gryaznov Ph.D. | Chief Scientific Officer |
| Linda Moreira | Company Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 27, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2026 | 8-K | Current Report |
| Apr 8, 2026 | 8-K | Current Report |
| Apr 7, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 7, 2026 | ARS | Filing |
| Apr 7, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 7, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 27, 2026 | 8-K | Current Report |